Join to View Full Profile
11100 Euclid AveCleveland, OH 44106
Phone+1 216-844-3951
Fax+1 216-844-5759
Dr. Bajor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013- University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
Case Western Reserve University School of MedicineClass of 2007
Certifications & Licensure
OH State Medical License 2016 - 2027
PA State Medical License 2007 - 2016
American Board of Internal Medicine Medical Oncology
Clinical Trials
- CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer Start of enrollment: 2016 Sep 12
Publications & Presentations
PubMed
- Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment.Veronica Mears, Nikolas Naleid, Omkar Pawar, Jennifer Eva Selfridge, Madison Conces
JCO Oncology Practice. 2025-09-01 - 1 citationsCITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid t...J Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y Chung
BJC Reports. 2025-02-27 - 1 citationsSafety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M Bauer
Journal of Immunotherapy and Precision Oncology. 2025-02-01
Press Mentions
Combining Two Cancer Drugs Can Be Effective in Treating Specific Type of Colorectal Cancer, Study ShowsMay 2nd, 2022
Adoptive Cell TherapyDecember 12th, 2018
Immunotherapy Combo Appears Safe, Shrinks Metastatic Melanoma TumorsJune 2nd, 2015- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
